CompletedPhase 4

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

Belgium, Germany, Italy6 participantsStarted 2014-09-29

Plain-language summary

This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕Treatment with any investigational drug unless it is received as part of a Novartis sponsored MS study lasting less than 1 month

What they're measuring

Participants Who Experienced at Least One Qualifying Cardiovascular Adverse Event

Timeframe: Within 6 months of qualifying event up to 64 months

Trial details

NCT IDNCT02232061

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-01-24

Results submitted2021-01-21

View on ClinicalTrials.gov More Multiple Sclerosis trials